LA JOLLA DIAGNOSTICS INC
SC 13D, 2000-05-02
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: LA JOLLA DIAGNOSTICS INC, PRE 14A, 2000-05-02
Next: EAGLE CAPITAL MANAGEMENT LLC, 13F-HR, 2000-05-02



                                 SCHEDULE 13D

                        RELATING TO THE COMMON SHARE OF
                           LA JOLLA DIAGNOSTICS, INC.


Item 1.     SECURITY AND ISSUER.

     This Statement on 13D (this "Statement") relates to the common shares (the
"Shares"), no par value, of La Jolla Diagnostics, Inc., a California
corporation ("La Jolla").  The principal executive office of La Jolla is
located at 7855 Ivanhoe Ave., Suite 322, La Jolla, CA 92037.

Item 2.     IDENTITY AND BACKGROUND.

     (a)    This Statement is being filed by Stephen C. Roberts, M.D.
            ("Filer").

     (b)    The address for Filer is 6542 Regency Lane, No. 204, Eden Prairie,
            MN  55344.  Filer's mailing address for purposes of this filing is
            c/o Robert W. Blanchard, Esq., 800 Silverado St., Second Floor,
            La Jolla, CA 92037.

     (c)    Filer is currently the President and Secretary and a Director of
            La Jolla.  During the last five years, Filer has not been convicted
            in a criminal proceeding (excluding traffic violations or similar
            misdemeanors).

     (d)    During the last five years, Filer has not been a party to a civil
            proceeding of a judicial or administrative body of competent
            jurisdiction which subject Filer to a judgment, decree or final
            order enjoining future violations of, or prohibiting or mandating
            activities subject to, federal or state securities laws or finding
            any violation with respect to such laws.

     (e)    Filer is a citizen of the United States of America.

Item 3.     SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

     Filer acquired the Shares reported herein in consideration of La Jolla's
purchase of substantially all of the assets of AmTech Scientific, Inc. ("AMI"),
a Nevada corporation, in which Filer, a shareholder of AMI, had to surrender
2,750,000 shares of the common stock of AMI.

Item 4.     PURPOSE OF TRANSACTION.

     As stated hereinabove, Filer acquired the Shares as part of an asset
purchase by La Jolla of AMI's assets.  Filer has no other purpose that must be
reported herein.

Item 5.     INTEREST IN SECURITIES OF THE ISSUER.

     (a)    Filer beneficially owns 2,450,000 shares of common stock, or
            approximately 12% of the common stock outstanding of 20,466,005 as
            of March 15, 2000.

     (b)    Filer has the sole power to vote or to direct the vote and the
            sole power to dispose or direct the disposition of the common stock
            reported as beneficially owned by such Filer.

     (c)    On or about February 14, 2000, Filer transferred without
            consideration 300,000 shares of common stock as a gift ("Gift") to
            certain family members (the "Donees").  Filer effected the
            aforementioned disposition by directing La Jolla's transfer agent
            to issue new certificates to the Donees and to himself to reflect
            the Gift.

     (d)    No person other than Filer has the right to receive or the power
            to direct the receipt of dividends from, or the proceeds from the
            sale of, any Shares.

     (e)    Not applicable.

Item 6.     CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
            RESPECT TO SECURITIES OF THE ISSUER.

     Presently, there are no outstanding contracts, arrangements,
understandings or relationships with respect to the Shares.

Item 7.     MATERIAL TO BE FILED AS EXHIBITS.

     There are no other materials to be filed herewith.


                                  SIGNATURE


     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Dated:  May 1, 2000


- -----------------------------------
Stephen C. Roberts, M.D., President



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission